Omeros Corporation
OMERHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOmeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. At a $701.3M market cap, Omeros Corporation ranks as a small-cap company within healthcare. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Market Cap
$701.3M
Beta
2.55
P/E (TTM)
8.50
P/E (Fwd)
-62.52
EPS (TTM)
$1.14
EPS (Fwd)
$-0.15
ROE
—
ROA
-25.2%
Cash
$135.3M
Total Debt
$226.6M
Free CF
$181.0M
52W Change
188.4%
Annual Financials
Cash vs Debt
On the balance sheet, OMER has $135.3M in cash with $226.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $181.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing.
Omeros Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Omeros Corporation's trajectory.